_1777370220974_847775619.png&w=48&q=75){kind=small}
Moderna stocks rise on melanoma vaccine success
Moderna and Merck announced positive results from a late-stage trial of their combined personalized mRNA vaccine and immunotherapy for melanoma skin cancer. The study showed the treatment reduced cancer recurrence and prevented spread in high-risk patients, with no new safety issues reported. Shares of Moderna and Merck increased significantly following the announcement.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)